Coronary Heart Disease Treatments
Find Coronary Heart Disease Treatments
Generic Name
Pravastatin
FDA approval date: April 25, 2006
Classification: HMG-CoA Reductase Inhibitor
Form: Tablet
What is Pravastatin?
Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor indicated : To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol without clinically evident coronary heart disease ., To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD., As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia., As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with:, Primary dysbetalipoproteinemia., Hypertriglyceridemia.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment